2022
Other Conditions
23 Century · Beike
Read paper
At our core, 23C stands against the speculation that often surrounds regenerative medicine. Over two decades, our research network has published peer-reviewed findings on mesenchymal stem cells, MLNK cell immunotherapy, and the secretome, and we have subjected our protocols to the scrutiny of the international scientific community.
This dedication to rigorous research sets us apart from cell therapy providers that rely on testimonial and unsubstantiated claims. The library below is our evidence base, curated by condition category. Not everything a patient wants to know is in the literature yet. We will tell you honestly when that is the case.
Peer-reviewed studies published by 23 Century and our Beike research network, grouped by condition. Each entry links to the full paper.
23C-authored case report evaluating the safety and visual outcomes of subtenon Wharton’s Jelly-derived MSC injection in a retinitis pigmentosa patient.
23C-authored 1–2 year follow-up of four RP patients receiving subtenon WJ-MSC implantation, assessing long-term safety, feasibility, and visual outcomes.
Our medical team can contextualise research findings for your case, including where published outcomes align with your diagnosis and where they diverge. We will flag the limitations, not just the highlights.
Speak with the Medical Team